



THE DAY TRADING ACADEMY  
—SUCCESS WEALTH FREEDOM—  
Let's Create Your Lifestyle

November 28, 2014 - October Investment Update 4 – By Jeffrey Hagenmeier



We begin our last update for October by looking at the September 28<sup>th</sup> recommendation to purchase Gogo, the airline internet stock. It was listed for **\$16.31 USD** (United States Dollar) at that time. The stock closed on **November 26<sup>th</sup>** at \$16.05 USD. The stock is down \$0.26 after reaching a high of \$17.88. The recommendation for **Gogo** is to **continue to hold** your shares. The target should be set for **\$19.00 USD for short term investors, \$20.00 USD for medium term investors with longer term investors** holding out for **\$22.00 USD**.

**Short term investors** in **Arch Coal** were advised to sell their positions, when the price had dipped back down to \$2.53 to lock in their **21.05% gains**. The original price of purchase was **\$2.09 on October 31<sup>st</sup>**. Shares closed this passed Wednesday at \$2.41 USD. The recommendation at this time is **to hold**. **Medium and long term investors** should **set their targets** at **\$3.00** and **\$4.00** respectively.

**GOLDCORP** **Goldcorp** is the next company on our list. The recommendation for purchase was made on October 3<sup>rd</sup> when the stock listed for **\$22.62 USD**. Last week a share of the stock sold for \$20.61. On November 26<sup>th</sup> shares finished at \$20.92 after giving back 0.34 cents. Although the stock is still down \$1.70, the recommendation is to **continue to hold shares** in this company. The **target** for **short and medium term investors** can be set at **\$24.00 USD**. **Long term investors** should leave their **target** at **\$28.00 USD**. When gold and silver prices recover so will shares in the company.

**Short term investors** in **Amira Nature Foods** were advised to sell their positions when the stock reached \$17.05. This was when the stock had **increased 10%** in value from the time of purchase which was on October 27<sup>th</sup>. At that time the stock was available for \$15.50. The stock has since declined to \$15.03. The fundamentals of the company remain strong so the recommendation is





THE DAY TRADING ACADEMY  
—SUCCESS WEALTH FREEDOM—  
Let's Create Your Lifestyle

to **continue to hold**. The **target** can remain at **\$18.60** for **longer term investors**.

BioCryst Pharmaceuticals have seen some improvement since last week. The stock has **increased in price \$1.03** ending Wednesday of this week at **\$11.38**. When the stock was originally offered as a recommendation on **October 24<sup>th</sup>** it sold for **\$11.83 USD**. The prospects of the company remain positive, so the advisement is to **continue to hold**. **Targets** can be placed between **\$14.00** and **\$15.00 USD**. This will allow a profit margin of 20% to 25%.



**Tekmira** was a stock recommended to you on October 09<sup>th</sup> along with **Chimerix**. They could of been purchased the following day for **\$22.80** and **\$31.06** respectively. The **target** for Chimerix set at **\$35.50** was reached on October 16<sup>th</sup> after regular business hours. It was a return of 14% for the investor, since the share price had increased a total of **\$4.44**, when it broke through the target price. Tekmira on the other hand, began to fade as soon as the scare of Ebola left world headline news outside of Africa. The stock has declined over 6 dollars since that time. It closed Wednesday at **\$16.13 USD** after a daily loss of \$0.18. The low for the stock was reached on November 5<sup>th</sup> when a share could be bought for \$15.12. On November 17<sup>th</sup> it bounced up briefly to a high of \$17.24 USD.

Since then, it has stayed mostly in the \$16.00 -\$17.00 range. Tekmira is a Canadian based company that has a number of products in development for treatments in cancer and infectious diseases. As a **long term investment** Tekmira is still a good opportunity, because the company continues to develop products, that are useful in the treatment of a variety of diseases and infections. If you are strictly a **short term investor** you can **cut your losses** now, or as a **medium term investor** wait for a brief bounce in the stock above the **\$17.00 to \$19.00 USD** range.

Our biggest disappointment for the month was **Sarepta Therapeutics**. When the stock was recommended to you on October 19<sup>th</sup>, it sold for \$22.22. This was at the height of the Ebola scare. The company founded in 1980 has over 170 medical patents issued and 150 pending. The primary products of the company are Morpholinos, which inhibit reproduction of a wide variety of viruses in clinical



SAREPTA  
THERAPEUTICS



THE DAY TRADING ACADEMY  
—SUCCESS WEALTH FREEDOM—  
Let's Create Your Lifestyle

studies. On Friday October 24<sup>th</sup>, the stock reached a high for the month of **\$23.56**. The **target** was still set at **\$26.00 USD**.

Then came the news that the company drug *eteplirsen*, used to treat DMD (*Duchenne muscular dystrophy*) had hit a snag in a regulatory update. The proposed filing with the FDA had now been moved to mid 2015, from late 2014. The new drug application was now in limbo.

By Monday October 27th the stock was down to \$15.91, and by Tuesday \$15.12. On Wednesday of this week a month later, the stock increased a total of **\$0.29** an increase of **1.76%** for the day. It ended the session at **\$16.81**. This means the stock is still **down \$5.41** from the original purchase price. The recommendation at this point for all investors in the stock, is **to hold** it until it has at least recovered the cost of the original investment, or has made back some of the losses incurred. I base this decision partly on the performance of the stock over the last year, with a low of **\$14.31** and the high of **\$40.00**. It is still an innovative company with great potential, that has taken a hit because of a temporary setback, that will change over time.